More: 2008 Gastrointestinal Cancers Symposium (GCS)

An Update From the Gastrointestinal Cancers Symposium CME

January 25 - 27, 2008, Orlando, Florida

Author Information and Disclosures

This activity is not sanctioned by, nor a part of, the 2008 Gastrointestinal Cancers Symposium.

Release Date: May 15, 2008; Valid for credit through May 15, 2009

Credits Available
Physicians - maximum of 0.75 AMA PRA Category 1 Credit(s)™ for physicians

To participate in this internet activity: (1) review the target audience, learning objectives, and author disclosures; (2) study the education content; (3) take the post-test and/or complete the evaluation; (4) view/print certificate View details.

Legal Disclaimer

The materials presented here do not reflect the views of Medscape or the companies providing unrestricted educational grants. These materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. All readers or continuing education participants should verify all information and data before treating patients or employing any therapies described in this educational activity.

The materials presented here were prepared by independent authors under the editorial supervision of Medscape and do not represent a publication of the 2008 Gastrointestinal Cancers Symposium. These materials and the related activity are not sanctioned by the 2008 Gastrointestinal Cancers Symposium or the commercial supporter of the conference and do not constitute an official part of that conference.

Copyright © 2008 Medscape.
Medscape
Learning Objectives

Upon completion of this activity, participants will be able to:

  1. Discuss the latest data presented at the ASCO GI meeting on the management of pancreatic cancer, including data on combination and novel therapies
  2. Review the latest clinical trial results presented at the ASCO GI meeting relating to the management of colorectal cancer
  3. Describe the importance of KRAS mutation in patients with metastatic colorectal cancer
Authors and Disclosures

M. Wasif Saif, MD, MBBS
Disclosure: M. Wasif Saif, MD, MBBS, has disclosed that he has received grants for clinical research from Avalon, Biogen Idec, PhytoCeutica, Samyang, and Taiho and has served on the speaker's bureau for Amgen, Bristol-Myers Squibb, Genentech, ImClone, Pfizer, Roche, and sanofi-aventis.


Margie Miller
Disclosure: Margie Miller has disclosed no relevant financial relationships.


Jill W. Chamberlain
Disclosure: Jill W. Chamberlain has disclosed no relevant financial relationships.


Ammar Hasan, PharmD
Disclosure: Ammar Hasan, PharmD, has disclosed no relevant financial relationships.
 
Medscape
Medscape, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Medscape, LLC designates this educational activity for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Contact This Provider

All material on this website is protected by copyright, Copyright © 1994-2008 by Medscape. This website also contains material copyrighted by 3rd parties.